Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients
© Nambu et al; licensee BioMed Central Ltd. 2011
Received: 10 July 2011
Accepted: 13 October 2011
Published: 13 October 2011
Chest wall injury after stereotactic radiotherapy (SRT) for primary lung cancer has recently been reported. However, its detailed imaging findings are not clarified. So this study aimed to fully characterize the findings on computed tomography (CT), appearance time and frequency of chest wall injury after stereotactic radiotherapy (SRT) for primary lung cancer
Materials and methods
A total of 177 patients who had undergone SRT were prospectively evaluated for periodical follow-up thin-section CT with special attention to chest wall injury. The time at which CT findings of chest wall injury appeared was assessed. Related clinical symptoms were also evaluated.
Rib fracture was identified on follow-up CT in 41 patients (23.2%). Rib fractures appeared at a mean of 21.2 months after the completion of SRT (range, 4 -58 months). Chest wall edema, thinning of the cortex and osteosclerosis were findings frequently associated with, and tending to precede rib fractures. No patients with rib fracture showed tumors > 16 mm from the adjacent chest wall. Chest wall pain was seen in 18 of 177 patients (10.2%), of whom 14 patients developed rib fracture. No patients complained of Grade 3 or more symptoms.
Rib fracture is frequently seen after SRT for lung cancer on CT, and is often associated with chest wall edema, thinning of the cortex and osteosclerosis. However, related chest wall pain is less frequent and is generally mild if present.
Stereotactic radiotherapy (SRT) for primary lung cancer has recently attracted attention because of its promising treatment effects [1–10]. A recent report demonstrated that SRT achieved a good survival rate for patients with non-small cell lung carcinoma, comparable to those of surgery . SRT has now been applied not only to medically inoperable patients but also to operable ones. In the near future, SRT might become an alternative treatment to surgery for stage I non-small lung carcinoma.
One major concern that must always been taken into consideration when selecting treatment methods is treatment sequelae. SRT is generally considered a safe treatment, with fewer complications than surgery. However, several studies have reported complications in SRT, such as radiation pneumonitis [11, 12] and chest wall injury, including rib fracture [5–7, 13–16]. Frequencies of rib fracture after SRT have already been reported in several investigations. However, detailed CT findings of chest wall injury have yet to be clarified.
The present study therefore aimed to fully characterize detailed CT findings of chest wall injury after SRT for primary lung cancer using thin-section CT.
The institutional review board approved all study protocols. Written informed consent was obtained from all patients prior to participation in this study.
Characteristics of the 177 primary lung cancer patients enrolled in this study.
Lung cancer patients (n = 177)
77.3 ± 7.0 (55-92)
*Gender (male: female)
**Range of follow-up period (median)
Tumor diameter (average ± standard deviation)
8-55 mm(30.0 ± 9.1)
central tumors: peripheral tumors
Method of radiotherapy (48Gy/4fr:60Gr/10fr:70Gr/10fr)
Methods of radiotherapy
SRT was performed using noncoplanar 10 dynamic arcs. A total dose of 48-70Gy at the isocenter was administered in 4-10 fractions, and approximately 80% isodose line of prescribed dose covered planning target volume (PTV) using a 6 MV X-ray, comprising three different methods, namely 48Gy/4fractions, 60Gy/10fractions, and 70Gy/10fractions, (Table 1). We essentially used 60Gy/10fractions but when tumor measured more than 3 cm (i.e. T2) 70Gy/10fractions was used, and cases that were registered in a certain clinical trial were treated with 48Gy/4fractions. The dose was not constrained by surrounding normal tissues including chest wall. Heterogeneity corrections were made in all cases.
After adjusting the isocenter of the PTV to the planned position in a unit comprising a CT scanner and linear accelerator, irradiation was performed under patient-controlled breath-holding and radiation beam switching.
Preradiotherapeutic and follow-up CT were performed using the same 16 multidetector row scanner (Aquilion 16 (Toshiba Medical Systems, Otawara, Japan)) and with the identical protocols.
Parameters for CT scanning were as follows: peak voltage 120 kVp, tube rotation time 0.5 second, slice collimation 1.0 mm, and beam pitch 0.94. Tube currents were determined by an automatic exposure control with the noise factor for determining the applied tube current was set at 11 (standard deviation) and the tube currents actually ranging from 110 to 400 mA.
Contrast-enhanced CT was performed for 116 patients (67.1%) after unenhanced CT. Contrast material (Omnipaque 300, Daiichi Sankyo, Tokyo) in a volume tailored to the body weight of each patient (600 mg iodine/kg body weight) was injected from the anterior cubital vein within a fixed injection time of 50 s (i.e. injection rate was variable.). CT scans were started at 60 and 120 s after beginning of the contrast injection.
These data were reconstructed into 5 mm sections. Thin-section CT (slice thickness, 1 mm) was also produced for regions that included tumor or radiation-induced opacities targeting the affected lung, which was mainly used for the evaluation of chest wall injury.
Preradiotherapeutic CT was performed within 1 month before SRT, while follow-up CT was performed at 3 and 6 months after the completion of the radiotherapy, and every 6 months thereafter.
Preradiotherapeutic CT was interpreted by either of two chest radiologists (A.N, E.S) in our institution. Maximum tumor size and the shortest distance between the tumor margin and chest wall (tumor-chest wall distance) were measured on 1 mm contrast-enhanced CT with a reconstruction kernel for viewing lung parenchyma as a part of the radiology report. Maximum tumor size was defined as the maximum dimension of a tumor in all of axial CT sections that included the tumor.
Follow-up CT was also examined by either of the same radiologists with special attention to abnormal findings of the chest wall in addition to routine radiological assessment. Rib fracture in this study was defined as a disruption of cortical continuity with malalignment. Thinning of cortex was defined as a focal area of cortex with a thickness less than half of the surrounding normal cortex. Osteosclerosis was defined as an area of increased attenuation comparable to cortex in the medulla of rib.
The time at which each finding first appeared after the completion of SRT was reviewed. Final outcomes of rib fractures during the follow-up period were also assessed on follow-up CT.
Follow-up of patients
Every patient was basically asked to visit our clinic at 3, 6, and every 6 months thereafter after the completion of radiotherapy. At every visit, a thorough examination was performed, consisting of inquiry focusing on pain at the chest wall near the irradiated tumor and respiratory symptoms, physical examination by an attending radiation oncologist, blood test, and CT. Clinical symptoms considered related to chest wall injury after SRT were graded according to the criteria for pain in Common Terminology Criteria for Adverse Events, version. 3. Chest radiologists interpreted the results of CT just after the examinations. If the patient complained of pain, analgesics were prescribed as appropriate.
Evaluation of dosimetry
Data analyses were performed retrospectively using the prospectively interpreted radiology reports.
First, we calculated the crude incidence of rib fracture after SRT on follow-up CT during the follow-up periods of the patients. As crude incidence may underestimate actual incidence of rib fracture, we also performed a Kaplan-Meier method to obtain a more accurate estimate of incidence of rib fracture. We also assessed the relationship between rib fracture and related findings in terms of time frame.
Second, we determined the threshold tumor-chest wall distance on preradiotherapeutic CT to discriminate patients who with rib fractures from those without. Frequencies of rib fracture when the tumor-chest wall distance was less than or equal to the threshold distance and when the distance was 0 mm were also calculated.
Third, we evaluated the frequency of clinical symptoms.
Fourth, mean BED3 and BED3 ≥ 50 Gy were calculated in fracture and non-fracture groups and were compared between the two groups using unpaired t test. Fisher's exact test or χ2 test was used to see differences between groups.
Value of p < 0.05 were considered statistically significant.
All statistical analyses were performed using IBM SPSS Statistics version 18(New York, USA).
Frequency of rib fractures after SRT
Appearance time and frequencies of the rib fractures and related findings
Appearance time ranges (months)*
Crude frequency of each finding
Frequency at 24 months by Kaplan-Meier method
Thinning of the cortex
Chest wall edema
Imaging findings of rib fracture and related findings and appearance times
Symptoms of rib fracture
Frequency and degree of chest wall pain
Degree of pain*
Fracture group (n = 41)
Non-fracture group (n = 136)
Grade 3 and 4
Threshold tumor-chest wall distance in the occurrence of rib fracture
Frequency of rib fracture in relation to tumor-chest wall distance
Tumor-chest wall distance(mm)
Frequency at 24 months by Kaplan-Meier method
Maximum BED3 of the chest wall in patients with and without rib fracture, and threshold dose for rib fracture occurrence Mean BED3 of the chest wall was 240.7 ± 38.7 in 26 patients with rib fracture and 146.8 ± 74.5 in 22 patients without rib fracture, representing a significant difference between groups (p < 0.001). The lowest BED3 that resulted in rib fracture was 152.4 Gy. Mean chest wall volume (cc) with BED3 > 50Gy was 110.3 ± 45.0cc in the fracture group and 50.1 ± 59.8 in the non- fracture group, again representing a significant difference (p < 0.001). The minimum volume that resulted in rib fracture was 25cc.
Our results demonstrated that the development of rib fracture after SRT is not uncommon with a frequency of 23.2% for the whole study population. Not unexpectedly, frequency increased with closer proximity of the tumors to the chest wall, from 31.3% ≤16 mm to 36.7% at 0 mm. The reported frequencies of rib fracture after SRT vary widely among investigators, ranging from 3% to 21.2% [5–7, 13–16]. Our result is closest to that reported by Petterson, et al., who reported the highest frequency (21.2%) among the previous reports . We speculate that these discrepancies are mainly caused by differences in the methods for estimating frequency. Petterson, et al. and the present study obtained frequencies based on follow-up CT, whereas other studies based frequencies on findings for patients who complained symptoms. That is, differences may be largely due to whether asymptomatic patients with rib fracture were likely to be included in frequency calculations. Our clinical experience supports this speculation. Differences in follow-up periods, methods of SRT or the proportion of tumors close to the chest wall may also have contributed to the discrepancies between studies. The frequency of rib fracture reported by Petterson, et al. is still lower than our result despite the fact that they used a higher prescribed SRT dose than we did. This may be because thin-section CT in the present study may have allowed sensitive detection of rib fracture.
In Kaplan-Meier method, the frequency of rib fracture was calculated to be even higher (27.4% at 24 months). This incidence is considered to be a more accurate estimate of frequency of rib fracture as there were censored cases during the follow-up periods.
The frequency of rib fracture is also more common in SRT for lung cancer than in breast conserving surgery combined with radiotherapy, which has a reported frequency of 0.3-2.2% [17, 18], probably due to much higher dose delivered to the rib in SRT when tumors are close to the chest wall.
Rib fractures occurred at a mean of 21.2 months (range, 4-58 months) after SRT, mostly within 30 months after completion of SRT, and were frequently preceded by chest wall edema, thinning of the cortex of the rib or sclerosis of the medulla of the rib. We may summarize the typical course of chest wall injury after SRT as depicted on thin-section CT as follows: at several months after SRT chest wall edema first appears. The cortex then becomes thinner and the medulla sometimes becomes sclerotic in a mottled fashion, and the affected rib eventually undergoes fracture. These CT findings presumably correspond to soft tissue edema and changes in bone vascularity due to increased permeability or occlusion of the capillaries caused by irradiation of the soft tissue, and a decrease in number of osteoblasts resulting in decreased collagen production, in turn causing osteopenia and subsequent bone injury . Osteosclerosis after radiotherapy is considered to represent reactive bone formation caused by remaining osteoblast cells .
Under such conditions, the rib becomes extremely vulnerable and often fractures. Although these bone changes may actually represent insufficiency fracture , radiation osteitis , callous formation secondary to microtrabecular fracture or osteonecrosis , we did not use these terms as we had no pathological confirmation of such findings. We therefore employed the common terms for imaging findings.
We think that these preceding findings may be usable as predictors of rib fracture. Prediction of rib fracture may be informative to the referring physicians as well as to patients as we might initiate treatment for chest wall pain related to the forthcoming rib fracture in advance or possibly take some preventive measures against rib fractures. Although the frequency of clinical symptoms was not high in patient with rib fracture and the clinical symptoms were generally not severe, most symptomatic patients had rib fracture. Therefore, prediction of rib fracture will clinically be important.
In addition, bone sclerosis or focal loss of cortex may be mistaken for metastasis. Familiarity with these findings will therefore minimize the potential for confusion.
The outcomes of rib fracture were non-union in 28 patients, including 14 patients with pseudoarthrosis and bony union in 13. Needless to say, the proportion of union and non-union largely depends on the duration of follow-up and the prescribed dose to tumors. However, we can at least say that a substantial proportion of rib fractures after SRT for lung cancer can remain a state of non-union for a long time after SRT and that pseudoarthrosis is not uncommon. However, the outcomes of rib fracture seem unrelated to the frequency of clinical symptoms.
A tumor-chest wall distance of 16 mm appears to represent a threshold value, beyond which rib fracture did not occur, in our series. This threshold offers a concise and convenient reference value. Undoubtedly, the risk of rib fractures depends much more on the dose delivered to the rib and therefore a dosimetry-based evaluation can provide a more accurate estimate of the risk of rib fractures. However, dosimetry can only be produced after SRT is chosen as the treatment. Our approach can provide a patient or referring physician with information about the risk of rib fracture based only on preradiotherapeutic CT before decision is made to undergo SRT. Our result may not be simply applicable to patients in other institutions as prescribed doses differ among institutions, but will be valid when prescribed doses are less than or equal to our own.
Mean BED3 of the chest wall (240.7 ± 38.7 Gy) and mean chest wall volume (cc) with BED3 ≥ 50Gy (110.3 ± 45.0cc) in 26 patients with rib fracture were much higher than those (146.8 ± 74.5Gy and 50.1 ± 59.8cc) in 22 patients without rib fracture, with statistical significances, respectively. These values may also be usable to predict the risk of rib fracture. The lowest BED3 that resulted in rib fracture was 152.4Gy. The threshold BED3 for producing rib fracture seemed to be around 150Gy, but further investigation is necessary to make a definitive conclusion.
This study has some limitations that must be considered. First, we regarded the appearance time of rib fracture and other related findings as that when these findings were first seen on follow-up CT. However, these events would actually have occurred within the interval of time since the previous CT. The present study would thus have overestimated time that elapsed until these events.
Second, for BED3 of chest wall, only a small number of cases from the study population were sampled. This was because of the limited capability of our treatment planning computer for data handling, which requires a substantial amount of time to reproduce a dosimetry. Calculating dosimetries of all cases is obviously the best way to obtain a threshold BED, but we believe that our random sampling method provided a clear and concise reference value, which would offer a benchmark when considering risk of rib fracture in clinical practice. Third, the method of SRT for lung cancer has yet to be standardized. So, our results cannot be simply applied to other institutions.
Rib fracture is seen with high frequency after SRT for lung cancer when the tumor is close to the chest wall. Chest wall edema and thinning and osteosclerosis of the cortex represent related findings that often precede rib fracture and might be predictive of a forthcoming rib fracture. However, related chest wall pain is less frequent and is generally mild if present.
- Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, Wong JR, Kusano S: Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51: 666-670. 10.1016/S0360-3016(01)01703-5View ArticlePubMedGoogle Scholar
- Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 10: 1623-1631.View ArticleGoogle Scholar
- Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63: 1427-1431. 10.1016/j.ijrobp.2005.05.034View ArticlePubMedGoogle Scholar
- Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007,2(7 Suppl 3):94-100.View ArticleGoogle Scholar
- Nyman J, Johansson KA, Hultén U: Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Lung Cancer 2006, 51: 97-103. 10.1016/j.lungcan.2005.08.011View ArticlePubMedGoogle Scholar
- Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M: Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006, 45: 796-801. 10.1080/02841860600913210View ArticlePubMedGoogle Scholar
- Fritz P, Kraus HJ, Blaschke T, Mühlnickel W, Strauch K, Engel-Riedel W, Chemaissani A, Stoelben E: Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer 2008, 60: 193-199. 10.1016/j.lungcan.2007.10.005View ArticlePubMedGoogle Scholar
- Haasbeek CJ, Lagerwaard FJ, de Jaeger K, Slotman BJ, Senan S: Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 2009, 115: 587-594. 10.1002/cncr.24068View ArticlePubMedGoogle Scholar
- Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, Kimura T, Karasawa K, Arimoto T, Hareyama M, Kikuchi E, Shirato H: Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys 2009, 75: 683-687. 10.1016/j.ijrobp.2008.11.026View ArticlePubMedGoogle Scholar
- Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T: Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys 2010, in press.Google Scholar
- Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ: A Dose-Volume Analysis of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2010, in press.Google Scholar
- Takeda A, Ohashi T, Kunieda E, Enomoto T, Sanuki N, Takeda T, Shigematsu N: Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys 2010, 77: 685-690. 10.1016/j.ijrobp.2009.06.001View ArticlePubMedGoogle Scholar
- Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM: Chest wall volume receiving > 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76: 796-801. 10.1016/j.ijrobp.2009.02.027View ArticlePubMedGoogle Scholar
- Pettersson N, Nyman J, Johansson KA: Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009, 91: 360-368. 10.1016/j.radonc.2009.03.022View ArticlePubMedGoogle Scholar
- Voroney JP, Hope A, Dahele MR, Purdie TG, Franks KN, Pearson S, Cho JB, Sun A, Payne DG, Bissonnette JP, Bezjak A, Brade AM: Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009, 4: 1035-1037. 10.1097/JTO.0b013e3181ae2962View ArticlePubMedGoogle Scholar
- Milano MichaelT, Constine LouisS, Okunieff Paul: Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiation Oncology 2008, 3: 36. 10.1186/1748-717X-3-36PubMed CentralView ArticlePubMedGoogle Scholar
- Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, Herzog A, Harris JR: Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992, 23: 915-923. 10.1016/0360-3016(92)90895-OView ArticlePubMedGoogle Scholar
- Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK: Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 2002, 9: 543-549. 10.1007/BF02573889View ArticlePubMedGoogle Scholar
- Bluemke DA, Fishman EK, Scott WW Jr: Skeletal complications of radiation therapy. Radiographics 1994, 14: 111-121.View ArticlePubMedGoogle Scholar
- Kwon JW, Huh SJ, Yoon YC, Choi SH, Jung JY, Oh D, Choe BK: Pelvic bone complications after radiation therapy of uterine cervical cancer: evaluation with MRI. AJR Am J Roentgenol 2008, 191: 987-994. 10.2214/AJR.07.3634View ArticlePubMedGoogle Scholar
- Bragg DG, Shidnia H, Chu FC, Higinbotham NL: The clinical and radiographic aspects of radiation osteitis. Radiology 1970, 97: 103-111.View ArticlePubMedGoogle Scholar
- Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2010, in press.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.